Can you take HRT if you have diabetes?
Yes, many women with diabetes can take menopause hormone therapy. Well-controlled diabetes on its own isn't a contraindication, but it raises the importance of your heart and blood-vessel history, which helps decide the form of HRT and whether online care is a sensible place to start.
First, two quick definitions so the rest of this page is easy.
- HRT (hormone replacement therapy), also called menopausal hormone therapy, usually means estrogen for symptoms like hot flashes and night sweats. If you still have a uterus, it usually also means a progestogen (progesterone or a similar hormone) to protect the uterine lining.
- A contraindication is a medical reason a treatment shouldn't be used. Having diabetes and having a contraindication are not the same thing.
Why so many women with diabetes were told no
Diabetes raises the risk of heart disease and stroke. After the Women's Health Initiative study in 2002, HRT got a reputation for raising those same risks. Put the two together and "no HRT with diabetes" became a common rule of thumb.
The research since then has been more reassuring than that rule. Here's what major groups say now:
- The European Society of Endocrinology (October 2025) recommends that well-controlled diabetes is not considered a contraindication, and says transdermal estrogen is "the preferred choice." (ESE guideline, R 3.4)
- The European Menopause and Andropause Society (EMAS) reached the same conclusion in its menopause-and-diabetes guide: diabetes isn't a contraindication, and the plan should follow your heart risk. (EMAS clinical guide, Maturitas 2018)
- The FDA approved label changes on February 12, 2026, removing heart disease, breast cancer and probable dementia statements from the boxed warning of the first six HRT products to be updated. (FDA announcement)
- The American College of Obstetricians and Gynecologists (ACOG) published a new menopause guideline on October 15, 2026. The official endorsement summary from the American College of Osteopathic Obstetricians and Gynecologists (ACOOG) says it strongly recommends systemic hormone therapy for hot flashes in women without contraindications, with initiation before 60 or within 10 years of natural menopause; starting later needs individual risk review. (ACOOG endorsement summary)
What hasn't changed
A few things matter just as much as they always did:
- If you have a uterus, whole-body estrogen usually needs a progestogen. Estrogen alone can thicken the lining and raise uterine cancer risk.
- A past heart attack, stroke or clot still means a specialist-level conversation, not a quick start.
- The label change didn't make HRT risk-free. It changed how the warnings are presented. Your exact product's label still matters. Our 2026 label changes explainer has the details.
Start with the problem you want solved
"HRT" covers very different treatments. Before anything else, name your main problem:
- Hot flashes, night sweats, broken sleep → whole-body (systemic) treatment or a non-hormonal medicine.
- Vaginal dryness, pain with sex, repeat UTIs → often a low-dose vaginal treatment, which is a separate and gentler conversation.
- Blood sugar that's suddenly harder to control → your diabetes team first. HRT isn't a diabetes treatment.
Many women are dealing with more than one. That's normal. The map below helps you sort it out.
Your diabetes and HRT route map: find your row
Find the row (or rows) that match you. Each one shows what current guidance points to, the question to ask, and whether online care is a reasonable place to start. Several rows can apply at once.
Diabetes + HRT route map
Built by The HRT Index from the European Society of Endocrinology (2025), EMAS (2018), the Endocrine Society (2015), The Menopause Society (2022), British Menopause Society (2025), the AUA and FDA drug labels. It helps you prepare a conversation. It doesn't diagnose you, approve treatment or pick a medicine.
| Your situation | What current guidance points to | Ask your clinician | Where to start | Gala fit |
|---|---|---|---|---|
| Well-controlled type 2, under 60 or within 10 years of your last period, no heart disease, blood pressure and cholesterol in range | Well-controlled diabetes isn't a contraindication. EMAS notes oral estrogen may be fine when heart risk is low; ESE prefers transdermal. | "Which form fits my history, and why?" | Online care can fit after review of other risks | Option to explore; confirm diabetes, age and state acceptance |
| Type 2 plus extra heart-risk factors (treated high blood pressure, high triglycerides, higher body weight, smoking) | Estrogen through the skin first, plus a progestogen that doesn't worsen blood sugar or fats, such as micronized progesterone | "Should I use a patch or gel instead of a pill?" | Online care can fit after review of overall risk and blood pressure | Patch listed; confirm provider acceptance |
| Type 1 diabetes | Little direct research; usual HRT safety rules apply; blood sugar may swing more around menopause | "How will you and my diabetes team share information if my readings change?" | Menopause clinician plus your endocrinologist | Possibly, with your diabetes team involved |
| Blood sugar has become unpredictable, or you're having repeated lows | Sort out the cause first; menopause symptoms and lows can feel alike | "What should I record, and when should I call?" | Your diabetes team first | Not first |
| Past heart attack, stroke, TIA or blood clot, or you've been told your heart risk is high | Routine whole-body HRT is generally not used; non-hormonal options first | "Which treatments are safe for my history?" | In-person first | In-person review first |
| 60 or older, or more than 10 years past your last period, and starting HRT for the first time | Benefit-risk is less favorable; needs a careful individual review | "Is a low dose, a patch or local treatment better for me?" | Menopause-experienced clinician; in-person is wise | Only after that review |
| You take a GLP-1 (Ozempic, Wegovy, Mounjaro, Zepbound) | UK guidance suggests discussing estrogen through the skin and a non-oral progestogen; direct HRT evidence is limited | "How will my uterine lining be protected while I'm on this medicine?" | Online care can fit if that question is answered | Possibly — ask first |
| Mostly vaginal dryness, pain with sex or repeat UTIs | Low-dose vaginal estrogen; U.S. urology guidance recommends it for repeat UTIs when there's no reason to avoid estrogen | "Is local treatment enough for my symptoms?" | Online care can fit after symptom and history review | Local option listed; clinician review required |
| You can't or don't want to take hormones | FDA-approved non-hormonal medicines exist; kidney and liver health affect which ones fit | "Which option fits my kidney and liver numbers?" | Online care can fit if the service can review required labs and follow-up | Non-hormonal options listed; confirm medicine and monitoring |
| Unexplained bleeding, possible pregnancy, or possible menopause before 40 | Needs evaluation before any HRT decision | "What needs to be ruled out first?" | In-person first | Evaluation first |
The Gala column matches its published menu to the question in each row. It does not confirm that Gala will accept your diabetes history, age or state. Gala's clinicians decide who they treat.
If you're in one of the first two rows — well-controlled type 2, under 60 or within 10 years of your last period, none of the closer-review issues above, and fine paying cash — you can look at an online option now and keep this page open for the questions. Gala lists estradiol as a pill or a patch, micronized progesterone, vaginal estradiol and non-hormonal options. Its HRT offer advertises $69 a month; confirm which medicines and any tests are included in your plan, with a clinician deciding what's appropriate.
Cash-pay. Treatment depends on clinician review and your state. Affiliate link.
Does type 1 or type 2 diabetes change the answer?
The evidence is much stronger for type 2 diabetes than for type 1. That affects how confidently a clinician can talk about blood-sugar effects, but it doesn't shut women with type 1 out of the menopause conversation.
Type 2 diabetes: the best-studied group
Most HRT research in women with diabetes involved type 2. In that group, studies point the same way: HRT doesn't seem to worsen blood sugar, and the treatment decision turns on heart and clot risk, not the diabetes label. (We cover the blood-sugar numbers below.)
What that doesn't mean: HRT isn't a diabetes treatment, and it doesn't replace anything your diabetes team prescribes.
Type 1 diabetes: plan who does what
A 2013 Cochrane review on HRT in type 1 diabetes found only one small trial, and that trial also included women with type 2. (Cochrane review) That review is now old, with a search that ended in 2012. A newer narrative review still describes the evidence as sparse, and notes that women with type 1 may reach menopause earlier and see more swings in blood sugar during the transition. (Endocrine Connections review, 2025)
Because there's less research, coordination matters more. Before starting, agree on:
- Who reviews your glucose data (often your endocrinologist).
- Who reviews your menopause treatment (the HRT prescriber).
- How they share information.
- What should prompt an earlier call — for example, more frequent or more severe lows.
If you use a continuous glucose monitor, your existing data can help both clinicians see whether anything changes after you start.
Is there an A1C number that rules out HRT?
None of the major guidelines we reviewed sets a universal A1C cutoff for HRT. ESE says "well-controlled" diabetes isn't a contraindication but doesn't define a number.
A1C (also called HbA1c) is a blood test that reflects your average blood sugar over roughly the past three months. (NIDDK) It's one piece of the review. If your diabetes is newly diagnosed, recently changed, or hard to control right now, ask whether it makes sense to steady things first. An individual service may also have its own rules, so ask them directly.
The right online menopause care isn't the same for every woman — it depends on your symptoms, what you've already tried, your age, your state and your health history. Some situations belong with an in-person clinician first. Use The HRT Index's Find My HRT Path tool to explore a featured care option for your situation — and to flag when online care isn't the right starting point — before your first consult.
Free, about 60 seconds, no email required. It asks five questions: what's bothering you most, what you've tried, your age, your state, and health history a clinician should know about. It helps with care navigation only. It can't decide whether HRT is safe for you, and it doesn't manage your diabetes. We may earn a commission from the providers it features. How the tool works.
Patch or pill: which HRT is safer if you have diabetes?
When you have diabetes, guidance generally prefers estrogen through the skin — a patch, gel or spray — especially if you also have other heart-risk factors. A patch isn't automatically safe for everyone, though, and an estrogen-only patch doesn't protect the uterine lining by itself.
Why the route matters
Transdermal means "through the skin." Here's the plain difference:
- A pill is swallowed, absorbed through the gut and passes through the liver first. That "first pass" tells the liver to make more clotting proteins and can raise triglycerides (a type of blood fat) and nudge blood pressure.
- A patch, gel or spray goes straight into the bloodstream and skips that first pass. The Endocrine Society notes these preparations have less effect on blood pressure, triglycerides and blood-sugar handling. (Endocrine Society guideline)
The Menopause Society says transdermal routes and lower doses may reduce the risk of blood clots and stroke. (The Menopause Society 2022 position statement) Much of the clot comparison comes from observational studies, so think of it as "lower risk," not "no risk."
The heart-risk grid that drives the decision
Diabetes raises heart risk, but it doesn't tell you which row you belong in. Your clinician considers your full history before using a heart-risk estimate to guide the HRT discussion.
Choosing HRT by 10-year heart risk (Endocrine Society, 2015)
| Estimated 10-year heart risk | What the 2015 guideline suggests when starting near menopause |
|---|---|
| Low (under 5%) | HRT can be considered |
| Moderate (5–10%) | HRT can be considered — choose transdermal |
| High (over 10%), or known heart attack, stroke or artery disease | Non-hormonal options first; routine systemic HRT is generally avoided |
Source: Endocrine Society menopause guideline. These are discussion categories, not validated HRT safety cutoffs. Your clinician must also assess diabetes complications, established heart disease, clot risk and other contraindications; you can't estimate your number from diabetes alone.
EMAS adds one nuance: for women with type 2 diabetes and low heart risk, oral estrogen may be preferred, while transdermal estradiol is preferred when there are heart-risk factors such as obesity. (EMAS diabetes factsheet)
The main treatment types, side by side
| Treatment | What it's for | FDA-approved or compounded? | What to ask |
|---|---|---|---|
| Estrogen through the skin (patch, gel, spray) | Whole-body symptoms like hot flashes and night sweats | FDA-approved products exist; confirm the exact product you're prescribed | "Why does this route fit my history?" |
| Estrogen pill | Whole-body symptoms | FDA-approved products exist; a different risk conversation than the patch | "How do the risks compare for me?" |
| Progestogen (usually with whole-body estrogen, if you have a uterus) | Protecting the uterine lining | FDA-approved oral and combined products exist; an IUD used for HRT lining protection is off-label in the U.S. | "What protects my lining, and how?" |
| Low-dose vaginal estrogen (cream, tablet, ring) | Vaginal dryness, pain with sex, some urinary symptoms | FDA-approved products exist; some vaginal rings are whole-body doses, so check the exact product | "Is this meant as local treatment?" |
| Compounded hormones | Custom-mixed for one person | Not FDA-approved. "Bioidentical" describes the molecule, not approval | "Why this instead of an approved product?" |
The FDA says compounded drugs are not FDA-approved and that it doesn't check their safety, effectiveness or quality before they're sold. (FDA on compounding) Many FDA-approved products — including estradiol patches and micronized progesterone — are bioidentical too. More in compounded vs FDA-approved HRT.
Which progesterone fits best with diabetes?
If you have a uterus and use whole-body estradiol, you need lining protection with a progestogen. Guidance favors types with a neutral effect on blood sugar and blood fats. The Endocrine Society names micronized progesterone (a body-identical progesterone capsule) as one such option. (Endocrine Society guideline) EMAS lists progesterone among its preferred choices too.
Lining protection matters a little more with diabetes, because diabetes is itself linked to a higher risk of uterine (endometrial) cancer. Ask how your lining will be protected and what bleeding you should report.
Other options include combined estrogen-progestogen patches. On October 19, 2026, the FDA approved a generic once-weekly estradiol and levonorgestrel patch for women with a uterus. (FDA announcement, October 20, 2026) A hormonal IUD is sometimes used for lining protection, but that use is off-label in the U.S.
What if you can't get your patch?
Demand for estradiol patches has climbed since the FDA began its labeling review in late 2025, and many women have had trouble filling their usual brand. On September 3, 2026, the FDA said estradiol patches remain available, that supply had nearly doubled over the past year, and that availability can vary by brand and pharmacy. (FDA patch update)
If your patch is out of stock:
- Ask your pharmacist whether another FDA-approved estradiol patch can be substituted.
- Ask your prescriber about other transdermal estradiol forms, such as a gel or spray.
- Don't switch to a pill, stop, or change your dose on your own. The FDA says the same.
If you already take HRT tablets
A general article isn't a reason to change your prescription yourself. It is a good reason to ask: "Now that I have diabetes (or it's changed), does my current route still fit?" If heart history or cholesterol is part of the picture, see HRT and heart disease and HRT and high cholesterol.
For more on forms, see estradiol patch reviews and estradiol pill reviews.
Will HRT raise your blood sugar?
In studies of women with diabetes, HRT more often lowered blood sugar slightly than raised it. It's not a diabetes treatment, though, and your own readings may shift in either direction, so agree with your diabetes team on what to watch.
What the studies show
In women who already have diabetes: a 2023 meta-analysis in Diabetes Care pooled 19 randomized trials with 1,412 women, about 4% of whom had type 1. HRT lowered A1C by about half a percentage point (0.56) and fasting glucose by about 1.15 mmol/L, which is roughly 21 mg/dL. Half the studies had a high risk of bias, and there was too little type 1 data to draw conclusions. The authors' bottom line: in type 2, expect a neutral-to-beneficial effect on blood sugar. (Speksnijder et al., Diabetes Care, 2023; abstract reproduced by a medical society journal)
In women without diabetes: in the Women's Health Initiative trial of oral conjugated estrogens plus medroxyprogesterone, 3.5% of women developed treated diabetes, compared with 4.2% on placebo over an average 5.6 years. That is a difference of 0.7 percentage points; the study's analysis of when diabetes developed found a 21% lower relative hazard. (Margolis et al., Diabetologia 2004) The original estrogen-alone analysis found a smaller difference that was not statistically significant. (Bonds et al., 2006) These results describe those oral regimens, not every HRT product.
What those numbers do and don't mean
- Good news for a common fear. If you've worried HRT will wreck your A1C, the trial evidence doesn't support that for type 2.
- Not a reason to take HRT. Expert groups agree HRT isn't approved or appropriate to prevent or treat diabetes. (The Menopause Society 2022 position statement) It's for menopause symptoms.
- Not a reason to cut your diabetes medicine. Any change to diabetes treatment belongs to the clinician who manages it.
- Blood sugar doesn't pick your route. Some research suggests pills affect glucose more than patches, but the route choice is about clot and heart risk, which matter more.
Track the pattern your team asks for
You don't need a new testing plan from us. Ask your diabetes team whether your current plan should change when you start. A simple log helps both clinicians:
| Write down | Example |
|---|---|
| Date and time | Tues, 3 a.m. |
| Symptom | Woke up soaked, heart racing |
| Glucose reading, if you checked under your usual plan | 68 mg/dL — follow the existing low-glucose plan; don't just log it |
| Recent medicine changes | Started estradiol patch 10 days ago |
| Question for your team | "Are these lows or night sweats?" |
Could a "hot flash" actually be low blood sugar?
Sometimes, yes. Sweating, a pounding heart, shakiness and waking at night can happen with both. Hypoglycemia means low blood sugar. If you use insulin or a sulfonylurea, check with your usual meter or CGM rather than guessing from how you feel, and follow your existing low-blood-sugar plan. (NIDDK on low blood glucose)
Severe confusion, a seizure or passing out needs emergency help right away — call 911. Don't wait for a menopause appointment.
Decide who handles which follow-up
Two services don't automatically talk to each other. Before you start, ask:
- "What changes should I report, and to whom?"
- "Who receives my glucose readings?"
- "When will we review how this is going?"
Who with diabetes should not start HRT online?
If you've had a heart attack, stroke, TIA or blood clot, have unexplained vaginal bleeding, a hormone-sensitive cancer or significant liver disease, start with a clinician who can examine you. A patch, a non-hormonal pill or a quiz result isn't a workaround for those histories.
Heart disease, stroke and blood clots
There's a difference between a risk factor (diabetes, high cholesterol, treated blood pressure) and a past event or established disease (a heart attack, stroke, TIA, stent, or blood clot). Risk factors often change the route. A past event usually changes whether whole-body HRT is used at all.
FDA labeling reflects this. The October 2026 generic combination patch, for example, lists past or active blood clots, past or active arterial clotting disease (such as stroke or heart attack), clotting disorders, liver disease, breast cancer, estrogen-dependent cancers and undiagnosed genital bleeding among the situations where it shouldn't be used. (FDA, October 20, 2026) The Endocrine Society suggests non-hormonal treatment first for women at high heart risk. For more, read HRT and heart disease and HRT contraindications.
Liver, kidney, cancer history and bleeding
- Liver disease matters for estrogen and for some non-hormonal medicines. Fatty liver is common with type 2 diabetes, so mention it.
- Kidney disease doesn't automatically rule out HRT, but severe kidney impairment rules out fezolinetant (Veozah), and other options have their own limits (more below).
- Your own cancer history is different from a family history. A personal history of breast or uterine cancer is a major reason to avoid whole-body estrogen; a family history is something to discuss.
- Unexplained bleeding, or any bleeding after menopause, needs to be checked before HRT. Don't let anyone wave it off as "just menopause."
Age and time since your last period
Starting HRT for the first time at 60 or older, or more than 10 years after your last period, is a different conversation. The Menopause Society says the benefit-risk balance looks less favorable then, because the absolute risks of heart disease, stroke, clots and dementia are higher. (Menopause Society 2022) That's about starting, not a rule that everyone must stop at 60. And if your periods stopped before 40, that's a separate situation that needs its own evaluation.
Get emergency help now (call 911) for chest pain, sudden shortness of breath, coughing up blood, weakness on one side, sudden severe headache, sudden vision changes or sudden confusion. A new painful, swollen leg needs urgent medical assessment; if it comes with breathing trouble or chest pain, call 911. (CDC blood-clot guidance)
Can you take HRT with metformin, insulin or a GLP-1 like Ozempic?
Your diabetes medicines don't automatically rule out HRT, but they shape the plan. Bring your full medicine list so a clinician or pharmacist can check your exact combination, and expect extra questions if you take a GLP-1.
Metformin, insulin and other glucose-lowering medicines
We didn't find a reason in the guidance we reviewed to treat metformin, insulin, SGLT2 inhibitors or other diabetes medicines as a blanket bar to HRT. But "no blanket bar" isn't the same as a checked combination. Ask: "Can these exact medicines be used together, and what should I watch for?"
If you use insulin or a sulfonylurea, ask whether your diabetes team wants you to check more often in the first weeks, since lows matter more with those drugs. Don't adjust doses on your own.
Ozempic, Mounjaro and other GLP-1 medicines
GLP-1-based medicines (including semaglutide and tirzepatide) slow how fast your stomach empties. That may affect how a swallowed hormone is absorbed, but the effect on HRT is not yet known. Patches, gels and sprays skip the gut, so delayed stomach emptying is not expected to affect their absorption.
The British Menopause Society's 2025 tool for clinicians, which is UK guidance, prefers estrogen through the skin in women with obesity and diabetes. It also suggests discussing a progestogen that isn't swallowed as a practical precaution during incretin treatment.
(BMS tool for clinicians, 2025) The evidence behind it is limited, and some of it comes from birth-control studies, not HRT trials. There are no direct data showing how semaglutide or tirzepatide affects the oral progestogen part of HRT or protection of the uterine lining. No U.S. guideline we reviewed addresses this pairing directly.
Ask: "I take [medicine name]. How will my uterine lining be protected, especially when my dose goes up?" Our full guide is Can you take HRT and GLP-1 together?
Can vaginal estrogen help dryness and UTIs if you have diabetes?
Often, yes. Low-dose vaginal estrogen treats dryness and painful sex, and U.S. urology guidelines recommend it to help prevent repeat UTIs after menopause when there's no reason to avoid estrogen. It works mainly where you apply it and doesn't treat hot flashes.
Why this matters more with diabetes
High blood sugar can make urinary and vaginal infections more likely. (NHS Scotland, My Diabetes My Way) After menopause, the tissue around the vagina and urethra also gets thinner. The two problems can stack.
Local treatment is a separate conversation
Low-dose vaginal estrogen (a cream, tablet or ring) works mostly in the vaginal and urinary tissue, with much less reaching the rest of your body than a patch or pill. At standard low doses, it generally doesn't need an added progestogen. That's a big reason it's a different, gentler conversation for women whose heart history makes whole-body HRT a harder call.
Two checks still apply: confirm the exact product, because a few vaginal products deliver whole-body doses, and report any new bleeding. (The Menopause Society)
Preventing repeat UTIs isn't the same as treating one
The American Urological Association recommends vaginal estrogen for peri- and postmenopausal women with recurrent UTIs, if there's no contraindication to estrogen. (AUA guideline) In the U.S., UTI prevention isn't a labeled use of vaginal estrogen products, so this is off-label. And it doesn't treat an infection you have right now. Burning, fever, back pain or unusual discharge needs a prompt check.
Ask: "Does this sound like menopause changes, an infection, or something else?" More in our vaginal estrogen guide and what estradiol vaginal cream is used for.
If dryness, pain with sex or repeat UTIs are your main problem, Gala lists low-dose vaginal estradiol cream or tablets as one of its four treatment types.
What if you can't or don't want to take hormones?
There are FDA-approved non-hormonal medicines for hot flashes. Two problems common with diabetes — kidney disease and liver disease — can rule some of them out, so bring your kidney and liver test results.
ACOOG's official summary of ACOG's October 2026 guideline describes strong recommendations for SSRI/SNRI antidepressants and neurokinin receptor blockers for hot flashes. These are options to discuss when you can't or don't want to use hormones. (ACOOG endorsement summary)
Non-hormonal hot-flash medicines: what diabetes can change
| Medicine | What it is | Checks that matter with diabetes |
|---|---|---|
| Fezolinetant (Veozah) | Once-daily NK3 receptor blocker, FDA-approved for moderate to severe hot flashes | Boxed warning for rare serious liver injury. Liver blood tests before starting, monthly for 3 months, then at months 6 and 9. Not for people with cirrhosis or severe or end-stage kidney disease (eGFR below 30 mL/min/1.73 m²), or who take medicines that block the enzyme CYP1A2. (Veozah label) |
| Elinzanetant (Lynkuet) | NK1/NK3 receptor blocker, FDA-approved in 2025 | Liver tests before starting and at 3 months. Can cause drowsiness; has drug-interaction and seizure warnings. Not recommended with moderate or severe liver impairment or end-stage kidney disease. Cannot be used during pregnancy. (Lynkuet label) |
| Low-dose paroxetine and other SSRIs/SNRIs | Antidepressants; the low-dose paroxetine product is FDA-approved for hot flashes. Other SSRIs/SNRIs are used off-label for this purpose | Check for drug interactions, including with tamoxifen |
| Gabapentin | Nerve medicine used off-label for hot flashes | Drowsiness; the dose depends on kidney function |
The SSRI/SNRI and gabapentin information is supported by The Menopause Society's 2023 nonhormone statement. Your clinician checks the exact medicine and current label.
Two practical notes:
- Kidney numbers: diabetic kidney disease is common. Veozah isn't an option if your eGFR is below 30 mL/min/1.73 m², including end-stage kidney disease. Other medicines may need dose changes.
- Liver numbers: fatty liver is common with type 2 diabetes. Make sure the prescriber has your recent liver tests.
Hormone-free doesn't mean risk-free, and deciding not to take anything right now is a valid choice too. Our non-hormonal options guide and fezolinetant guide go deeper. Gala's clinicians can also review non-hormonal options, including fezolinetant; if you have kidney or liver disease, start with a clinician who has your full lab history.
What to bring to your HRT appointment
You don't need to arrive with a chosen drug or dose. Bring a clear goal, your diabetes numbers and your questions, and let the clinician do the matching.
Your appointment preparation sheet
Fill this in on paper or on your own device. Nothing you write here is sent to us.
| Bring or write down | What to include | Why it matters for HRT | My information / notes |
|---|---|---|---|
| My main goal | The symptom I most want help with and how it affects sleep, work or life | Decides systemic vs local vs non-hormonal | Space to write notes for My main goal. |
| My diabetes care | Diabetes type; who manages it | Who needs to stay in the loop | Space to write notes for My diabetes care. |
| Latest A1C | Value, date and unit (% or mmol/mol), or "ask my diabetes team" | Baseline for follow-up | Space to write notes for Latest A1C. |
| Glucose records | The log or CGM report I already use; recent lows, highs or changed patterns | Spots lows that feel like hot flashes | Space to write notes for Glucose records. |
| Blood pressure | 7–14 days of home readings if I have them (free 14-day log) | Uncontrolled blood pressure changes timing and route | Space to write notes for Blood pressure. |
| Cholesterol panel, including triglycerides | Latest results and date | Pills can raise triglycerides; patches are gentler | Space to write notes for Cholesterol panel, including triglycerides. |
| Kidney and liver results | eGFR, urine albumin, liver tests, any fatty-liver diagnosis | Rules some non-hormonal medicines in or out | Space to write notes for Kidney and liver results. |
| Full medicine list | Names, forms and doses, including GLP-1, SGLT2, insulin, blood pressure medicines, hormones and supplements | GLP-1 medicines may affect swallowed hormones; checks for interactions | Space to write notes for Full medicine list. |
| Heart and clot history | Heart attack, stroke, TIA, stent, blood clot, clotting disorder | Decides in-person vs online and the route | Space to write notes for Heart and clot history. |
| Menopause and uterus details | Last period or period pattern; whether I have a uterus; any unexplained bleeding | Decides progestogen; bleeding gets checked first | Space to write notes for Menopause and uterus details. |
| Other history | Breast or uterine cancer (mine vs family), smoking, migraine with aura | Can change the route or rule out estrogen | Space to write notes for Other history. |
| Access | Insurance or cash, my state, pharmacy, online or in-person preference | Narrows where to go | Space to write notes for Access. |
Agree on follow-up
Write “not known” or “ask my clinician” if you do not have an answer. Keep the original units and dates. This sheet does not calculate risk, approve HRT, or choose treatment.
Glucose-data clinician: ____________________Menopause clinician: ____________________Review date: ____________________Call sooner if: ____________________
A past heart attack, stroke, TIA or blood clot, unexplained vaginal bleeding, hormone-sensitive cancer or significant liver disease calls for a clinician’s review first. Do not use a blank box as a sign that treatment is safe. This is care preparation only: follow your existing diabetes plan and do not change medicine based on this sheet.
Guide and evidence: this guide, the European Society of Endocrinology 2025 menopause guideline, and The Menopause Society 2022 hormone therapy statement are linked in the source and methods section.
Eight questions to ask, word for word
- "Is my diabetes itself a concern here, or is something else in my history driving the decision?"
- "What's my 10-year heart risk, and does that point me to a patch, a pill, or a non-hormonal option?"
- "Which progestogen would protect my uterine lining without worsening my blood sugar or cholesterol?"
- "I take [GLP-1 or other medicine]. Does that change which form you'd use?"
- "Should I check my blood sugar differently at first, and who do I tell if it changes?"
- "If my patch is out of stock, what's my backup?"
- "Which exact product would I get, and is it FDA-approved or compounded?"
- "What will I pay today and over the next three months, including visits, medicine and tests?"
Worked example (made up, not a patient story)
Here's how one woman might fill in the sheet. It ends in questions, not a treatment.
| Field | Example entry |
|---|---|
| Who she is | 53, type 2 diabetes for six years, has a uterus, last period two years ago |
| Main goal | Night sweats waking her three times a night |
| Medicines | Metformin, semaglutide (started four months ago), lisinopril |
| Numbers | A1C 7.0% (June); home BP averaging 128/80; triglycerides 210 mg/dL |
| History | No heart attack, stroke or clot; doesn't smoke |
| Access | Fine paying cash; prefers online |
| Rows that apply | "Type 2 plus extra heart-risk factors" and "You take a GLP-1" |
| Questions she'll lead with | #2, #3 and #4 |
| Result | A focused conversation about a patch and how her lining will be protected while on semaglutide — not a decision she makes alone |
Where can you get HRT if you have diabetes?
You can start with the clinicians who already manage your diabetes, a menopause-experienced clinician in your insurance network, or an online menopause service if your history fits. The best choice depends on your heart history, how complex your diabetes care is, and whether you need insurance.
Start with your current team when coordination matters most
If you have type 1 diabetes, kidney disease, a heart history, or blood sugar that's hard to control, your existing team is often the best first stop. Ask your primary care clinician or endocrinologist for a menopause-informed visit or referral. The Menopause Society keeps a directory of menopause practitioners. A listing doesn't guarantee insurance coverage or diabetes experience, so call and ask.
Gala: a strong cash-pay option for the right reader
If you have well-controlled type 2 diabetes, you're under 60 or within 10 years of your last period, none of the closer-review issues above applies, and you're comfortable with cash-pay online care, Gala is the online service we feature first. Here's why it lines up with this page, based on what Gala publishes:
- The route guidance favors is on the menu. Gala lists estradiol as a pill or a patch, so the transdermal option guidelines prefer for many women with diabetes is available to discuss.
- A lining-protection option is listed. Gala lists micronized progesterone to protect the uterine lining during estrogen treatment.
- Local and non-hormonal paths too. Vaginal estradiol cream or tablets for dryness, painful sex and repeat UTIs, and non-hormonal medicines including fezolinetant if hormones aren't right for you.
- One advertised price. Gala's HRT offer page advertises $69 a month, flat, with no insurance needed and no membership fee, and says your exact plan and price are shown before you pay. FSA and HSA cards are accepted.
- Ongoing care. Gala says provider messaging, symptom check-ins and dose adjustments are included for as long as you're treated, and prescriptions ship free.
- A real review, with a stated limit. Gala says a US-licensed clinician reviews your history before prescribing — usually within a day, Gala says, with a short video visit required in some states. Gala says it doesn't prescribe when the risk doesn't make sense.
Where Gala's own pages leave questions (from our October 2026 review)
| Topic | What Gala's pages say | What to ask before paying |
|---|---|---|
| Medication type | Main pages say FDA-approved bioidentical forms; an alternate HRT page carries a compounded-medication notice | "Is my product an FDA-approved finished product or compounded? Who makes it?" |
| Patch supply | Lists "pill or patch"; no brand or strength named; no gel listed | "Which patch? If it's out of stock, what's the backup?" |
| GLP-1 users | The $69 page lists progesterone as an oral capsule | "How will my lining be protected while I'm on a GLP-1?" |
| What $69 covers | Clinician visit, prescription and shipping, per Gala | "Does $69 cover both estradiol and progesterone? Are labs extra?" |
| Billing and cancelling | "Cancel anytime" on the offer page; the linked general refund policy requires notice 72 hours before your billing date and uses some weight-loss wording | "What's due today, how often am I billed, and does the 72-hour rule apply to HRT?" |
| Payment timing and refunds | The alternate HRT page says charged after approval. The linked general policy says charged when intake is completed and gives conflicting medical-disqualification refund terms | "Will I be charged before review, and what exactly is refunded if your clinician declines or later ends treatment?" |
| Diabetes | Not stated on the pages we reviewed | "Will your clinician review my diabetes history and labs? Should I upload my recent A1C and cholesterol?" |
| Insurance | Cash-pay only | If you need insurance or have Medicare, see the alternatives below |
These answers can change whether Gala is a good fit. Get them before paying. If you later leave, ask how refills, prescription transfers and records will be handled so your next prescriber can plan continuity. Our full Gala Health HRT review has the details.
"Gala's provider walked me through the options" — Allison, 51, quoted on Gala's hormone-health page. Provider-published testimonial; not independently verified. It doesn't describe diabetes care or predict results.
A 20-second self-check before you click:
- Am I under 60, or within 10 years of my last period?
- Have I never had a heart attack, stroke, TIA or blood clot, and has no clinician told me my heart risk is high?
- Am I comfortable paying cash (or with an HSA/FSA card)?
Three yeses, and none of the in-person-first issues above applies? Gala is worth a look. Bring your A1C, blood pressure and cholesterol numbers, ask about the patch, and get the answers in the table above before you pay.
Affiliate link. A Gala clinician decides whether any treatment is right for you.
Any no? That's useful to know. A heart history means an in-person clinician first. If age or time since menopause is the issue, start with a menopause-experienced clinician's review. If the only "no" is paying cash, the options below may fit better.
If insurance, a named product or more complex care comes first
| Gala Health | Midi Health | Your diabetes clinician or a menopause practitioner | Alloy | |
|---|---|---|---|---|
| Best for | Cash-pay, stable type 2, lower heart risk after clinical review; confirms the plan price before paying | Wants insurance and scheduled video visits | Type 1, heart history, kidney disease, Medicare, complex care | Wants products and prices published up front |
| Forms to discuss | Estradiol pill or patch; micronized progesterone; vaginal estradiol; non-hormonal incl. fezolinetant (per Gala) | Prescribes to your local pharmacy; product depends on your visit | FDA-approved options, subject to clinical need, coverage and pharmacy supply | Publishes a product menu with per-product prices |
| Advertised price | Advertised $69/month; exact bundle unconfirmed (checked Oct 24, 2026) | $250 first visit, $150 follow-up self-pay; medicine and labs extra (checked Oct 24, 2026) | Your copay and pharmacy costs | $49 consult; estradiol patch $100/month; progesterone from $23/month (checked Oct 24, 2026) |
| Insurance | No; HSA/FSA accepted | Many PPO plans; Medicare self-pay only with restrictions below; no Medicaid/Medi-Cal even as self-pay | Depends on clinician and plan; check Medicare participation | No |
| Diabetes edge | Patch and progesterone listed; confirm combined price | Pharmacy flexibility if a patch brand is short | Knows your diabetes and heart history | You see the product before paying |
| Our link | Affiliate | Direct, not monetized | Not monetized | Not monetized |
Check Midi's plan coverage on its pricing and insurance page, or browse Alloy's HRT menu. Midi says Medicare patients can self-pay, but claims for its visits and associated care cannot be submitted to Medicare; read its Medicare and Medicaid policy. For the full field, see our comparison of online HRT providers.
How much does HRT cost if you have diabetes?
Diabetes doesn't have one fixed HRT price. The treatment and monitoring you need can change the full cost. With good insurance or Medicare, your own clinician may cost least; if you're paying cash, compare the full first three months, not just the monthly headline.
Early costs by path
| Path | Due first | Recurring | Example: first three months | What's included | What's unknown | Checked |
|---|---|---|---|---|---|---|
| Gala HRT | Advertised $69; confirm the amount and charge timing before submitting payment | Advertised $69/month | $207 for three monthly charges (3 × $69), if that price covers the prescribed combination; incomplete until required extras are confirmed | Clinician review, prescription, shipping, messaging (per Gala) | Exact medication bundle; required labs; payment timing and applicable refund terms | Oct 24, 2026 |
| Midi Health (self-pay) | $250 after the first completed visit; card required at booking | $150 per completed follow-up | $400 for a first visit plus one follow-up, before medicine and labs | Visits only | Pharmacy cost; labs; how many follow-ups you'll need | Oct 24, 2026 |
| Alloy (patch + progesterone) | $49 consultation, then $300 for a three-month patch supply plus progesterone from $69 when the prescription order is approved | Medication from $369 every three months; patch alone $300 every three months | From $418 ($49 + $300 + $69); $349 for the patch alone if you don't need progesterone | Consult and listed product supplies | Final prescribed product price; any separate diabetes care or monitoring outside Alloy | Oct 24, 2026 |
| Your own clinician (insured) | Copay or deductible | Copays and pharmacy | Depends on your plan | Depends on your plan | Your deductible status | — |
These are worked examples from published prices, not quotes. Three monthly charges and a three-month supply are not a promise of an exact 90-day billing window. No promotions are included. If a required cost is unknown, the total is incomplete, not zero.
Sources: Gala HRT offer, Midi pricing and billing, Alloy patch, progesterone and billing. Alloy says it does not order or arrange blood tests; any separate diabetes monitoring stays with your usual care team. Alloy lab policy.
What it means: if Gala confirms that $69 covers both prescribed medicines and no required extras apply, its three-charge subtotal would be $207. Confirm that before comparing it with another provider's complete quote. If you need only one product, or you have insurance that covers a generic patch, another path may come in lower. Our HRT cost guide has more cost comparisons.
How we checked this guide
We used medical guidelines, FDA labeling and peer-reviewed studies for health claims, and provider pages for service claims. Our conclusions are editorial judgments from that evidence, not firsthand care or a medical review.
We applied The HRT Index Verification Standard and its five pillars, in this order:
| Pillar | What we checked for this guide |
|---|---|
| 1. Clinical legitimacy | Health claims come from the European Society of Endocrinology, EMAS, the Endocrine Society, The Menopause Society, FDA labels and announcements, the AUA and peer-reviewed studies — never provider marketing. A provider saying its clinicians are licensed isn't the same as us checking each one. |
| 2. Care quality | We looked for published follow-up, messaging and "we'll say no" policies. Advertised messaging doesn't prove diabetes coordination. |
| 3. Medication fit | We matched routes to diabetes and heart risk, separated systemic from local treatment, flagged lining protection and the GLP-1 question, and kept FDA-approved and compounded products separate. |
| 4. Price transparency | We separated amount due now, recurring charges and billing interval, and marked unknown costs as unknown. |
| 5. Access | We noted insurance, Medicare, state and age information where published, patch supply, and when in-person care should come first. |
Depth of review: documentation review, checked October 2026. No editor completed an intake, saw a clinician or bought medication. This guide does not publish scores. Read our methodology and affiliate disclosure.
Quick answers about HRT and diabetes
Can you take HRT with type 2 diabetes?
Often, yes. Well-controlled type 2 diabetes isn't considered a contraindication by European endocrine guidance; your heart and clot history helps decide the route and whether online care fits.
Can you take HRT with type 1 diabetes?
It's possible. There's little direct research, so your menopause prescriber and diabetes team should agree on how to watch your blood sugar.
Does HRT raise A1C?
In trials of women with type 2 diabetes, A1C went down slightly on average. Your own readings can still change, so keep tracking.
Can HRT cause diabetes?
Trials have not shown an increased diabetes risk from the HRT regimens studied. In the Women's Health Initiative, women on estrogen plus progestin developed treated diabetes less often than women on placebo. HRT still isn't used to prevent diabetes.
Is the patch better than the pill if you have diabetes?
Often. Guidance prefers estrogen through the skin for many women with diabetes, especially with other heart-risk factors. Low-risk women may still be offered a pill.
Can HRT replace my diabetes medicine?
No. HRT treats menopause symptoms. Any change to diabetes treatment belongs with the clinician who manages it.
Can I take HRT with Ozempic or Mounjaro?
Often, but tell your prescriber. GLP-1 medicines may affect swallowed hormones; direct HRT evidence is limited. UK guidance suggests discussing a patch or gel and a non-oral progestogen as a precaution.
Do I need extra blood tests before HRT?
Routine hormone-level tests usually aren't needed to start HRT in midlife. Your diabetes labs (A1C, cholesterol, kidney and liver tests) help the clinician choose, and some non-hormonal medicines require liver tests.
What if my doctor has already said no?
Ask whether the concern is the diabetes itself, another part of your history, or the specific treatment. If the reason is just "diabetes," a menopause-experienced clinician can give a second opinion — but a real contraindication still stands.
Do the 2026 FDA label changes mean HRT is safe for everyone?
No. The FDA removed some statements from the boxed warning on the first six updated products in February 2026. Contraindications still apply, and the exact product label still matters.
Are HRT pellets OK with diabetes?
Compounded hormone pellets are not FDA-approved, and an implanted dose cannot be readily adjusted or stopped. Ask whether an FDA-approved patch, gel or pill would meet your needs.
Can Find My HRT Path tell me if HRT is safe with my diabetes?
No. It's a free care-navigation tool. It points you to a featured online care option or to guidance when online care isn't the right starting point. A clinician decides whether HRT is right for you.
The bottom line
- Diabetes alone usually doesn't rule out HRT. Well-controlled diabetes isn't a contraindication in current European endocrine guidance.
- Your heart risk helps pick the form. With extra risk factors, a patch or gel usually comes first, with a progestogen if you have a uterus.
- HRT doesn't seem to worsen blood sugar in type 2 — but it's not a diabetes treatment, and type 1 needs closer teamwork.
- A heart attack, stroke, TIA, clot or unexplained bleeding means an in-person clinician first.
Still not sure where you fit? The free Find My HRT Path quiz looks at your symptoms, what you've tried, your age, your state and your health history, then shows a featured care option — or tells you when another starting point makes more sense. Bring your diabetes questions to the clinician either way.
Care navigation only. Not a diabetes assessment, eligibility check or treatment plan. The tool's published privacy explanation says your answers stay in your browser.
Keep reading: HRT contraindications · HRT and high blood pressure · HRT and heart disease · Can you take HRT and GLP-1 together? · Vaginal estrogen · Non-hormonal options · HRT for PCOS · Gala Health HRT reviews
Sources
Checked October 24, 2026 unless noted.
Guidelines and position statements
- European Society of Endocrinology. Clinical practice guideline for evaluation and management of menopause and the perimenopause. Eur J Endocrinol, October 2025 (R 3.4 on diabetes).
- Slopien R, et al. Menopause and diabetes: EMAS clinical guide. Maturitas, 2018; guidance cross-checked against EMAS's own 2022 diabetes factsheet.
- Stuenkel CA, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline, 2015 — full accepted manuscript.
- The Menopause Society. 2022 hormone therapy position statement, full official statement.
- The Menopause Society. 2023 nonhormone therapy position statement, full official statement.
- ACOG Clinical Practice Guideline No. 13, published October 15, 2026, as summarized in ACOOG's official October 23, 2026 endorsement.
- American Urological Association. Recurrent uncomplicated UTIs in women (current guideline page; see the menopause-society statement for the local-estrogen evidence discussed here).
- British Menopause Society. Use of incretin-based therapies in women using HRT: tool for clinicians, 2025 (UK guidance).
Studies and reviews
- Speksnijder EM, et al. Effect of postmenopausal hormone therapy on glucose regulation in women with type 1 or type 2 diabetes. Diabetes Care, 2023 — abstract reproduced by a medical society journal; numerical findings also checked against the ESE guideline.
- Margolis KL, et al. Effect of oestrogen plus progestin on the incidence of diabetes. Diabetologia, 2004.
- Bonds DE, et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia, 2006 (publisher abstract).
- Hormone replacement therapy for women with type 1 diabetes. Cochrane, 2013.
- Current evidence and research gaps in menopause management in women with type 1 diabetes. Endocrine Connections, 2025.
FDA and drug labels
- FDA. Labeling changes to menopausal hormone therapy products, February 12, 2026.
- FDA. Update on estradiol transdermal patch availability, September 3, 2026.
- FDA. Approval of a once-weekly generic hormone therapy patch, October 20, 2026.
- FDA. Compounding and the FDA: questions and answers.
- Veozah (fezolinetant) prescribing information, DailyMed, revised February 2026.
- FDA. Veozah rare serious liver-injury warning, boxed-warning update December 16, 2024.
- Lynkuet (elinzanetant) prescribing information, DailyMed, revised August 2026.
Patient resources
- NIDDK. The A1C test and diabetes.
- CDC. About venous thromboembolism.
- NIDDK. Low blood glucose (hypoglycemia).
- NHS Scotland, My Diabetes My Way. Diabetes and the menopause.
- The Menopause Society. Find a menopause practitioner.
Providers
- Gala Health. Hormone health, micronized progesterone, non-hormonal menu, $69 HRT offer, alternate HRT offer and linked general refund policy, read October 24, 2026.
- Midi Health. Pricing and insurance, billing and Medicare/Medicaid policy, checked October 24, 2026.
- Alloy. HRT, estradiol patch, progesterone, billing and lab policy, checked October 24, 2026.
The HRT Index is an independent editorial publication, not a healthcare provider, pharmacy or telehealth service. Nothing here is medical advice, a diagnosis or a treatment plan. For decisions about starting, stopping or changing hormone therapy or diabetes medicine, talk with a licensed clinician who knows your history. In an emergency, call 911.